Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 6.

Wick, W; Roth, P; Hartmann, C; Hau, P; Nakamura, M; Stockhammer, F; Sabel, M C; Wick, A; Koeppen, S; Ketter, R; Vajkoczy, P; Eyupoglu, I; Kalff, R; Pietsch, T; Happold, C; Galldiks, N; Schmidt-Graf, F; Bamberg, M; Reifenberger, G; Platten, M; von Deimling, A; Meisner, C; Wiestler, B; Weller, M (2016). Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. Neuro-Oncology, 18(11):1529-1537.

Suchorska, B; Weller, M; Tabatabai, G; Senft, C; Hau, P; Sabel, M C; Herrlinger, U; Ketter, R; Schlegel, U; Marosi, C; Reifenberger, G; Wick, W; Tonn, J C; Wirsching, H G (2016). Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial. Neuro-Oncology, 18(4):549-556.

Weller, Michael; Tabatabai, G; Kästner, B; Felsberg, J; Steinbach, J P; Wick, A; Schnell, O; Hau, P; Herrlinger, U; Sabel, M C; Wirsching, H G; Ketter, R; Bähr, O; Platten, M; Tonn, J C; Schlegel, U; Marosi, C; Goldbrunner, R; Stupp, R; Homicsko, K; Pichler, J; Nikkhah, G; Meixensberger, J; Vajkoczy, P; Kollias, S; Hüsing, J; Reifenberger, G; Wick, W (2015). MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. Clinical Cancer Research, 21(9):2057-2064.

Wick, W; Meisner, C; Hentschel, B; Platten, M; Schilling, A; Wiestler, B; Sabel, M C; Koeppen, S; Ketter, R; Weiler, M; Tabatabai, G; von Deimling, A; Gramatzki, D; Westphal, M; Schackert, G; Loeffler, M; Simon, M; Reifenberger, G; Weller, M (2013). Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology, 81(17):1515-1522.

Wick, W; Platten, M; Meisner, C; Felsberg, J; Tabatabai, G; Simon, M; Nikkhah, G; Papsdorf, K; Steinbach, J P; Sabel, M; Combs, S E; Vesper, J; Braun, C; Meixensberger, J; Ketter, R; Mayer-Steinacker, R; Reifenberger, G; Weller, M (2012). Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncology, 13(7):707-715.

Wick, W; Hartmann, C; Engel, C; Stoffels, M; Felsberg, J; Stockhammer, F; Sabel, M C; Koeppen, S; Ketter, R; Meyermann, R; Rapp, M; Meisner, C; Kortmann, R D; Pietsch, T; Wiestler, O D; Ernemann, U; Bamberg, M; Reifenberger, G; von Deimling, A; Weller, M (2009). NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide. Journal of Clinical Oncology, 27(32):5874-5880.

This list was generated on Sat Sep 23 12:37:29 2017 CEST.